- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00802412
Topiramate to Aid Smoking Cessation in Alcohol Dependent Men
December 6, 2016 updated by: VA Office of Research and Development
Topiramate to Aid Smoking Cessation in Recovering Alcohol Dependent Men
The purpose of this study is to determine whether topiramate is effective as an aid to smoking cessation for recovering alcohol dependent men.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a 12-week, double-blind, placebo-controlled trial to test the efficacy of topiramate versus placebo as an aid to smoking cessation for recovering alcohol dependent men.
Another aim of the study is to explore whether or not topiramate reduces relapse to alcohol use in patients with comorbid alcohol and nicotine dependence.
All participants will receive a standardized psychosocial intervention in combination with the medication (or placebo).
Following completion of the treatment phase of the study, participants will enter a 24-week follow-up period during which the longer-term outcome of the intervention will be assessed.
Study Type
Interventional
Enrollment (Actual)
132
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92161
- VA San Diego Healthcare System, San Diego, CA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Subjects will be included if they:
- are 18-70 years of age, inclusive;
- are male outpatients with a diagnosis of DSM-IV-TR nicotine dependence and alcohol dependence in early full remission (1-36 months abstinence);
- are current tobacco smokers who smoke an average of 10 or more cigarettes per day in the two months prior to the screening visit;
- are motivated to try to quit smoking and maintain abstinence from alcohol and other illicit drugs;
Exclusion Criteria:
Subjects will be excluded if they:
- have any clinically significant laboratory evidence of hematologic, hepatic, cardiovascular, renal, pulmonary, or thyroid disease;
- have a current significant neurologic, hepatic, renal, gastrointestinal, pulmonary, metabolic, cardiovascular, infectious, or endocrine disease;
- have a history of known hypersensitivity to topiramate;
- in the investigator's judgment, pose a current suicidal or homicidal risk;
- have taken any investigational drug within 30 days of baseline; and
- have a current seizure disorder or a history of severe alcohol withdrawal (alcohol withdrawal seizures, hallucinations / illusions, delirium tremens).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Topiramate
The subjects for the proposed study will be 180 currently smoking, treatment-seeking male veterans with alcohol and nicotine dependence.
Ninety subjects will be randomized to the topiramate arm and 90 subjects will be randomized to the placebo group.
|
Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42.
Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
Other Names:
|
Placebo Comparator: Placebo
90 participants, will receive matching placebo
|
Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
4-week Continuous Abstinence From Smoking
Time Frame: Weeks 8-12 of treatment.
|
This measure indicates the proportion of participants who did or did not smoke any cigarettes during the final 4 weeks of treatment, which represented weeks 8-12 of study participation.
|
Weeks 8-12 of treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Relapsing to Any Drinking or Illicit Drug Use
Time Frame: 12-week treatment phase, 36-week combined treatment and follow-up
|
Alcohol or illicit drug use during treatment or follow up.
|
12-week treatment phase, 36-week combined treatment and follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Robert M. Anthenelli, MD, VA San Diego Healthcare System, San Diego, CA
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
November 1, 2014
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
December 3, 2008
First Submitted That Met QC Criteria
December 3, 2008
First Posted (Estimate)
December 4, 2008
Study Record Updates
Last Update Posted (Estimate)
January 31, 2017
Last Update Submitted That Met QC Criteria
December 6, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEUA-003-08S
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Dependence
-
University Hospital, LilleCompleted
-
Tel-Aviv Sourasky Medical CenterMinistry of Health, IsraelUnknownAlcohol-dependenceIsrael
-
Pop Test Oncology LLCBaylor College of Medicine; Michael E. DeBakey VA Medical Center; Congressionally... and other collaboratorsCompletedPotential Treatment for Alcohol Dependence-Alcohol InteractionUnited States
-
DynamiCare HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA); RANDActive, not recruitingAlcohol Dependence | Alcohol Use Disorder | Drug DependenceUnited States
-
National Institute on Alcohol Abuse and Alcoholism...CompletedAlcohol Abuse | Alcohol Dependence (Primary Condition)United States
-
University Hospital, Gentofte, CopenhagenCompleted
-
Massachusetts General HospitalCompletedAlcohol Dependence | Drug Abuse | Alcohol Abuse | Drug DependenceUnited States
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
University of WashingtonU.S. Army Medical Research and Development CommandCompletedAlcohol Dependence | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
Clinical Trials on Topiramate
-
Johnson & Johnson Taiwan LtdCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Supernus Pharmaceuticals, Inc.Completed
-
University of CopenhagenR W Johnson Pharmaceutical Research InstituteTerminated
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedObesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Adult-Onset
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedObesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Adult-Onset
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedMigraine | Headache | Common Migraine | Classic Migraine